• Blockchain technology has the potential to improve transparency,
  trust, patient safety and patient engagement in oncology clinical
  trials
• Patients will be able to share real-time healthcare data with life
  sciences companies, enabling better access to information and unlock
  siloed data

NEW YORK & PARIS–(BUSINESS WIRE)–Embleema,
the patient-driven healthcare blockchain network for secure sharing of
personal health records, today announced a strategic partnership with Gustave
Roussy Institut, Europe’s leading cancer center, to develop
blockchain-based health data sharing applications for oncology clinical
research and development. Embleema will deploy its technology and
develop new standards for real-world oncology studies at the cancer
center.

Embleema brings its expertise and technological solutions to enable the
secure exchange of health data, allowing patients to consolidate all
their data on a single repository. Blockchain technology guarantees that
each patient can exercise full data sovereignty, while providing
researchers and pharmaceutical companies with an authenticated supply
chain of regulatory-grade data to evaluate the safety and efficacy of
new investigational drugs.

Embleema launched PatientTruth, the industry’s healthcare blockchain
platform that stores and distributes electronic medical records and
allows patients to assemble their own medical history, with full control
and access to personal data. Individuals can also receive digital tokens
in exchange for participation in clinical studies. Building on its
proprietary blockchain technology, Embleema is also developing a
decentralized platform for data sharing in clinical research. Blockchain
offers patient consent and smart contracts, that allow individuals to
tailor how they opt-in and share anonymous data. At any time, a patient
can cancel, modify access, or control the destination and use of their
data.

This strategic partnership will enable the integration of health data,
and consolidation onto a real world evidence data exchange, that will
enable patients of the Gustave Roussy Institut to access and control
their data. For the first time, healthcare data will become reusable for
life sciences research, an important step forward in breaking data silos
that typically slow down the development of new drugs.

“Our partnership with Embleema will define a new ethical model in drug
development, so individual healthcare data may be used to further
clinical research, in a transparent manner that fully respects patient
rights,” said Professor Alexander Eggermont, General Director of the
Gustave Roussy Institut. “Blockchain technology allows real world data
to finally be able to evaluate the effectiveness and safety of
treatments, and deliver new treatments to patients faster.”

Robert Chu, CEO of Embleema added: “We are honored to take part in this
strategic partnership with Gustave Roussy, which is internationally
recognized for the quality of care they provide to cancer patients and
their advanced research in immunotherapy and molecular medicine. By
streamlining the collection and sharing of clinical information, while
ensuring patient consent, Embleema aims to accelerate the development of
new drugs and improve the real-world data collection of existing
marketed drugs.”

Embleema has formed a Consortium that brings together patient advocacy
groups, medical providers like Gustave Roussy, life sciences companies,
technology companies, standardization bodies and regulators to define
and provide solutions that standardize the secure collection and
exchange of digital health data. This will serve to define
regulatory-grade “Real World Data” (RWD). Gustave Roussy will be one of
the first centers to allow its patients to take part in this new
exchange that allows regulators to assess the efficacy and safety of
health products on an ongoing basis.

About Embleema

Embleema
helps patients and pharma accelerate the availability of new treatments,
by fast-forwarding the exchange of data from the real world. It provides
a patient-driven healthcare blockchain network to allow patients to
share their consolidate health records securely. Hosted on a private
blockchain, Embleema’s consolidated, highly-secure repository provides
the healthcare ecosystem with an undisputed and holistic view of
patients’ medical history, while maintaining the patient’s data
sovereignty.

CEO Robert Chu left his role as Senior Vice President, Global Technology
Solutions at IMS Health to found Embleema in June 2017 and is supported
by a team of healthcare and technology executives from Harvard Medical
School, T-Systems, the Pharmaceuticals Division of Pierre Fabre and
iBionext and Nokia / Withings Digital Health.

For more information, please visit
www.embleema.com and follow Embleema on Twitter
@Embleema,
Telegram,
LinkedIn, and
Facebook.

About Gustave Roussy

Gustave Roussy, the leading cancer center in Europe, is a global center
of cancer expertise dedicated entirely to patients. It brings together
3,100 professionals whose missions are care, research and teaching. For
more information: www.gustaveroussy.fr

Contacts

Gustave Roussy
Claire Parisel
T: +33 1 42 11 50 59
M:
+33 6 17 66 00 26
[email protected]

Embleema
Investors
Alexis Normand
Embleema
33
6 76 98 06 43 (France)
781-353-8949 (US)
[email protected]

Media (Europe)
Jean-François Kitten
[email protected]

Media (US)
Kimberly Ha
KKH Advisors
917-291-5744
[email protected]